Biomedical Research Education & Training
Faculty Member

Fingleton, Barbara Mary, Ph.D.
Assistant Professor of Cancer Biology

Lab Url: N/A

Phone Number: 615-936 5877

Email Address: barbara.fingleton@Vanderbilt.Edu

Fingleton, Barbara's picture
Academic history
B.Sc., Dublin City Univ
Ph.D., Dublin City Univ, Ireland

Office Address   Mailing Address

715CA PRB [office]/ 734 PRB [lab]

771 PRB 37232-6840


Research Keywords
Inflammation, Proteolysis, colitis, IL4, IL13, MMP10, colon cancer,Cancer,Enzyme action,Knockout,Malignancy,Mouse

Research Specialty
Understanding function and how to therapeutically target inflammatory molecules in colitis and colon cancer

Research Description
My background is in the area of matrix metalloproteinases (MMPs) and how they contribute to cancer development and progression. I have been especially interested in testing drugs that can inhibit MMPs in cancer models and in understanding why such drugs have not been effective in human cancer patients. Lately, I have focused on some of the roles of specific MMPs in pre-cancerous inflammatory conditions, particularly colitis. We have identified a protective function for a specific MMP in colitis and are currently working on elucidating the mechanism. Additionally, I work on the cytokines IL4 and IL13 and their receptors ,and how these molecules can influence colon cancer development and progression. We use multiple mouse models combined with in vitro approaches to address the pleiotropic functions of these cytokines which affect both the epithelial cancer cells and the inflammatory infiltrate within tumors.

Publications
Barrett, CW, Fingleton, B, Williams, A, Ning, W, Fischer, MA, Washington, MK, Chaturvedi, R, Wilson, KT, Hiebert, SW, Williams, CS. MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. Cancer Res, 71(4), 1302-12, 2011

Koon, HB, Fingleton, B, Lee, JY, Geyer, JT, Cesarman, E, Parise, RA, Egorin, MJ, Dezube, BJ, Aboulafia, D, Krown, SE. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr, 56(1), 64-8, 2011

Fingleton, B. Inflammatory proteinase slips into tumor cells. Nat Med, 16(2), 161-3, 2010 PMCID:2902104

Fingleton, B, Lynch, CC. A new dress code for MMPs: cleavage optional. Dev Cell, 18(1), 3-4, 2010

Koller, FL, Hwang, DG, Dozier, EA, Fingleton, B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis, 31(6), 1010-7, 2010

Lynch, CC, Vargo-Gogola, T, Matrisian, LM, Fingleton, B. Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA. J Oncol, 2010, 530745, 2010 PMCID:2902104

Ogden, SR, Noto, JM, Allen, SS, Patel, DA, Romero-Gallo, J, Washington, MK, Fingleton, B, Israel, DA, Lewis, ND, Wilson, KT, Chaturvedi, R, Zhao, Z, Shyr, Y, Peek, RM. Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. Cancer Res, 70(1), 30-5, 2010

Stathopoulos, GT, Sherrill, TP, Karabela, SP, Goleniewska, K, Kalomenidis, I, Roussos, C, Fingleton, B, Yull, FE, Peebles, RS, Blackwell, TS. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med, 182(10), 1273-81, 2010 PMCID:2902104

Martin, MD, Carter, KJ, Jean-Philippe, SR, Chang, M, Mobashery, S, Thiolloy, S, Lynch, CC, Matrisian, LM, Fingleton, B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res, 68(15), 6251-9, 2008

Martin, MD, Fingleton, B, Lynch, CC, Wells, S, McIntyre, JO, Piston, DW, Matrisian, LM. Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. Clin Exp Metastasis, 25(8), 877-85, 2008 PMCID:2588650

Ogden, SR, Wroblewski, LE, Weydig, C, Romero-Gallo, J, O''Brien, DP, Israel, DA, Krishna, US, Fingleton, B, Reynolds, AB, Wessler, S, Peek, RM. p120 and Kaiso regulate Helicobacter pylori-induced expression of matrix metalloproteinase-7. Mol Biol Cell, 19(10), 4110-21, 2008 PMCID:2555941

Quarles, CC, Lepage, M, Gorden, DL, Fingleton, B, Yankeelov, TE, Price, RR, Matrisian, LM, Gore, JC, McIntyre, JO. Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI. Magn Reson Med, 60(3), 718-26, 2008 PMCID:2646120

Sinnamon, MJ, Carter, KJ, Fingleton, B, Matrisian, LM. Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol, 89(6), 466-75, 2008

Sinnamon, MJ, Carter, KJ, Sims, LP, Lafleur, B, Fingleton, B, Matrisian, LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis, 29(4), 880-6, 2008

Stathopoulos, GT, Sherrill, TP, Han, W, Sadikot, RT, Polosukhin, VV, Fingleton, B, Yull, FE, Blackwell, TS. Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis, 25(1), 43-51, 2008

Stathopoulos, GT, Sherrill, TP, Han, W, Sadikot, RT, Yull, FE, Blackwell, TS, Fingleton, B. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res, 6(3), 364-71, 2008

Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des, 13(3), 333-46, 2007

Fingleton, B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics, 4(3), 211-21, 2007

Fingleton, B. MMPs as therapeutic targets-Still a viable option. Semin Cell Dev Biol, 2007 PMCID:2677300

Fingleton, B, Carter, KJ, Matrisian, LM. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Cancer Res, 67(10), 4800-6, 2007

Fingleton, B, Powell, WC, Crawford, HC, Couchman, JR, Matrisian, LM. A Rat Monoclonal Antibody That Recognizes Pro- And Active MMP-7 Indicates Polarized Expression In Vivo. Hybridoma (Larchmt), 26(1), 22-7, 2007

Gorden, DL, Fingleton, B, Crawford, HC, Jansen, DE, Lepage, M, Matrisian, LM. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer, 2007

Lepage, M, Dow, WC, Melchior, M, You, Y, Fingleton, B, Quarles, CC, P??pin, C, Gore, JC, Matrisian, LM, McIntyre, JO. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging, 6(6), 393-403, 2007

Lynch, CC, Vargo-Gogola, T, Martin, MD, Fingleton, B, Crawford, HC, Matrisian, LM. Matrix Metalloproteinase 7 Mediates Mammary Epithelial Cell Tumorigenesis through the ErbB4 Receptor. Cancer Res, 67(14), 6760-7, 2007

Schwartz, DR, Moin, K, Yao, B, Matrisian, LM, Coussens, LM, Bugge, TH, Fingleton, B, Acuff, HB, Sinnamon, M, Nassar, H, Platts, AE, Krawetz, SA, Linebaugh, BE, Sloane, BF. Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res, 5(5), 443-54, 2007

Stathopoulos, GT, Sherrill, TP, Cheng, DS, Scoggins, RM, Han, W, Polosukhin, VV, Connelly, L, Yull, FE, Fingleton, B, Blackwell, TS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A, 104(47), 18514-9, 2007 PMCID:2141808

Acuff, HB, Carter, KJ, Fingleton, B, Gorden, DL, Matrisian, LM. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res, 66(1), 259-66, 2006 PMCID:1360653

Acuff, HB, Sinnamon, M, Fingleton, B, Boone, B, Levy, SE, Chen, X, Pozzi, A, Carbone, DP, Schwartz, DR, Moin, K, Sloane, BF, Matrisian, LM. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res, 66(16), 7968-75, 2006

Fingleton, B. Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci, 11, 479-91, 2006

Chen, X, Su, Y, Fingleton, B, Acuff, H, Matrisian, LM, Zent, R, Pozzi, A. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int J Cancer, 116(1), 52-61, 2005

Chen, X, Su, Y, Fingleton, B, Acuff, H, Matrisian, LM, Zent, R, Pozzi, A. An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice. Clin Exp Metastasis, 22(2), 185-93, 2005

Harrell, PC, McCawley, LJ, Fingleton, B, McIntyre, JO, Matrisian, LM. Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp Cell Res, 303(2), 308-20, 2005

Lynch, CC, Hikosaka, A, Acuff, HB, Martin, MD, Kawai, N, Singh, RK, Vargo-Gogola, TC, Begtrup, JL, Peterson, TE, Fingleton, B, Shirai, T, Matrisian, LM, Futakuchi, M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell, 7(5), 485-96, 2005

Fingleton, B, Menon, R, Carter, KJ, Overstreet, PD, Hachey, DL, Matrisian, LM, McIntyre, JO. Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res, 10(23), 7865-74, 2004

Gustavson, MD, Crawford, HC, Fingleton, B, Matrisian, LM. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol Carcinog, 41(3), 125-39, 2004

Hulboy, DL, Gautam, S, Fingleton, B, Matrisian, LM. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep, 12(1), 13-7, 2004

McIntyre, JO, Fingleton, B, Wells, KS, Piston, DW, Lynch, CC, Gautam, S, Matrisian, LM. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J, 377(Pt 3), 617-28, 2004 PMCID:1223892

Mohammed, FF, Smookler, DS, Taylor, SE, Fingleton, B, Kassiri, Z, Sanchez, OH, English, JL, Matrisian, LM, Au, B, Yeh, WC, Khokha, R. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet, 36(9), 969-77, 2004

Yang, L, DeBusk, LM, Fukuda, K, Fingleton, B, Green-Jarvis, B, Shyr, Y, Matrisian, LM, Carbone, DP, Lin, PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409-21, 2004

Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets, 7(3), 385-97, 2003

Fingleton, B. CMT-3. CollaGenex. Curr Opin Investig Drugs, 4(12), 1460-7, 2003

Coussens, LM, Fingleton, B, Matrisian, LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295(5564), 2387-92, 2002

Fingleton, B, Vargo-Gogola, T, Crawford, HC, Matrisian, LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia, 3(6), 459-68, 2002 PMCID:1506562

Vargo-Gogola, T, Crawford, HC, Fingleton, B, Matrisian, LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys, 408(2), 155-61, 2002

Vargo-Gogola, T, Fingleton, B, Crawford, HC, Matrisian, LM. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res, 62(19), 5559-63, 2002

Crawford, HC, Fingleton, B, Gustavson, MD, Kurpios, N, Wagenaar, RA, Hassell, JA, Matrisian, LM. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol, 21(4), 1370-83, 2001 PMCID:99589

Fingleton, B, Matrisian, LM. Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. Curr Opin Oncol, 13(5), 368-73, 2001

No?<, V, Fingleton, B, Jacobs, K, Crawford, HC, Vermeulen, S, Steelant, W, Bruyneel, E, Matrisian, LM, Mareel, M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci, 114(Pt 1), 111-118, 2001

Haro, H, Crawford, HC, Fingleton, B, MacDougall, JR, Shinomiya, K, Spengler, DM, Matrisian, LM. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest, 105(2), 133-41, 2000 PMCID:377425

Haro, H, Crawford, HC, Fingleton, B, Shinomiya, K, Spengler, DM, Matrisian, LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest, 105(2), 143-50, 2000 PMCID:377426

Nelson, AR, Fingleton, B, Rothenberg, ML, Matrisian, LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18(5), 1135-49, 2000

Crawford, HC, Fingleton, BM, Rudolph-Owen, LA, Goss, KJ, Rubinfeld, B, Polakis, P, Matrisian, LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene, 18(18), 2883-91, 1999

Fingleton, BM, Heppner Goss, KJ, Crawford, HC, Matrisian, LM. Matrilysin in early stage intestinal tumorigenesis. APMIS, 107(1), 102-10, 1999

Powell, WC, Fingleton, B, Wilson, CL, Boothby, M, Matrisian, LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol, 9(24), 1441-7, 1999

Fingleton, B, McDonnell, S. Cytokine regulation of matrilysin gene expression. Biochem Soc Trans, 25(2), 155S, 1997

McDonnell, S, Fingleton, B. Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors. Cytotechnology, 12(1-3), 367-84, 1993


Postdoctoral Position Available
No

Postdoctoral Position Details
N/A

Updated Date
01/02/2012